Developed by Clínic-IDIBAPS teams as part of the Clínic Barcelona Comprehensive Cancer Centre, this treatment confirms its therapeutic potential in a1
CAR T-cell therapy, a revolutionary technology originally developed for blood cancers, may also help in restoring the immune system in severe autoimm1
The international DESTINY-Breast05 trial, published in The New England Journal of Medicine, demonstrates that the antibody-drug conjugate trastu1
A team from Clínic-IDIBAPS has designed a new cellular immunotherapy strategy to enhance the immune system’s response against invasive fungal infecti1
Hospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulat1
Girem Full! (Let's Turn the Page!) is a charity event that aims to raise funds for cancer immunotherapy research by promoting reading.
Researchers at IDIBAPS- Hospital Clínic have developed and validated a new CAR-T therapy called ARI0003 at a preclinical level. The new therapy combi1
Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) combin1
Researchers at the Clínic-IDIBAPS coordinated a study that highlights the efficacy of migraine treatment with a monoclonal antibody, galcanezumab, in1
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
